CVS vs ELV vs HIMS Stock Comparison

Cvs Health, Elevance Health and Hims & Hers Health Prices as of Nov 16, 2026 Peers: Industry group
CVS CVS HEALTH Corp
$88.61 -4.1% 1M +13.9% 1Y
Market cap
$109.76B
P/E
9.9x
Revenue (TTM)
$420.61B
Div. yield
–
Managed Care Healthcare
7 wins
ELV Elevance Health, Inc.
$446.47 +4.3% 1M +37.0% 1Y
Market cap
$93.96B
P/E
18.3x
Revenue (TTM)
$201.83B
Div. yield
–
Managed Care Healthcare
2 wins

Head to Head

11 decided of 12

Cvs Health leads on 7 of the 12 questions below (Cvs Health 7, Hims & Hers Health 2, Elevance Health 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVSELVHIMSLeader
Larger companyMarket capitalisation $109.76B $93.96B $4.13B CVS
Cheaper on earningsLower P/E, profitable companies only 9.9x 18.3x -21.7x CVS
Cheaper on forward earningsLower price / next fiscal year consensus EPS 10.2x 14.3x — CVS
Faster revenue growthRevenue growth, trailing twelve months +6.7% +3.6% +29.8% HIMS
More profitableNet margin, trailing twelve months 2.6% 2.5% -6.6% CVS
Better return on capitalReturn on invested capital 9.7% 8.3% — CVS
Less leveragedLower net debt / EBITDA 2.3x -0.5x — ELV
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +13.9% +37.0% -49.8% ELV
Better 5-year returnAnnualised price return, 5 years -0.9%/yr +0.8%/yr +18.0%/yr HIMS
Less volatileAnnualised volatility, 1 year 35.2% 35.8% 91.2% CVS
Higher overall scoreMean of the five percentile scores vs peers 72/100 68/100 38/100 CVS

Percentile Scorecard

CVSELVHIMS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVSELVHIMS
Valuation 100 #1 of 27 81 #6 of 27 36 #64 of 99
Growth 80 #6 of 26 36 #17 of 26 24 #68 of 89
Profitability 84 #5 of 26 72 #8 of 26 33 #62 of 92
Financial Health 24 #20 of 26 68 #9 of 26 20 #83 of 103
Shareholder Returns 71 #6 of 18 82 #4 of 18 76 #16 of 63
Overall 72 68 38
  • CVS ranked among 27 companies in Healthcare Payers and Distributors
  • ELV ranked among 27 companies in Healthcare Payers and Distributors
  • HIMS ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVSELVHIMSSPY
1 month -4.1%+4.3%-33.9% -3.0%
3 months -5.8%+14.4%-35.2% -4.2%
6 months -7.7%+13.3%-16.7% +0.2%
Year to date +11.7%+27.4%-42.8% +8.5%
1 year +13.9%+37.0%-49.8% +10.1%
3 years +28.8%-3.6%+148.5% +64.1%
3 years, per year +8.8%-1.2%+35.5% +18.0%
5 years -4.4%+3.9%+128.6% +58.1%
5 years, per year -0.9%+0.8%+18.0% +9.6%
10 years +18.8%+222.6%— +239.6%
10 years, per year +1.7%+12.4%— +13.0%

Risk

MeasureCVSELVHIMSSPY
Volatility, 1Y 35.2%35.8%91.2% 13.8%
Downside volatility, 1Y 38.7%38.2%86.9% 14.2%
Beta vs S&P 500, 1Y -0.040.252.59 1.00
Return / volatility, 1Y 0.391.03-0.55 0.74
Max drawdown, 5Y -60.5%-51.2%-78.9% -25.4%
From 52-week high -19.8%0.0%-53.6% -5.0%
52-week high $110.55$446.47$40.02 $779.14
52-week low $70.08$280.74$14.52 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVSELVHIMS
P/E now vs peer median 10.4xmedian 25.2x 18.1xmedian 25.2x -24.2xmedian 22.4x
P/S now vs peer median 0.3xmedian 0.4x 0.5xmedian 0.4x 1.6xmedian 1.3x
EV/EBITDA now vs peer median 8.2xmedian 14.5x 9.6xmedian 14.5x -33.4xmedian 14.2x
P/FCF now vs peer median 7.3xmedian 16.5x 14.3xmedian 16.5x 145.7xmedian 19.0x
P/B now vs peer median 1.4xmedian 2.7x 2.1xmedian 2.7x 13.0xmedian 2.6x
PEG now vs peer median 1.22median 1.72 -7.75median 1.72 0.35median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVSELVHIMS
Revenue $420.61B $201.83B $2.87B
Gross profit $186.06B $53.35B $1.83B
Operating income $15.06B $7.70B -$232.48M
Net income $11.09B $5.13B -$190.81M
Free cash flow $15.57B $6.51B $31.68M
R&D – – $212.19M
EPS (diluted) $8.55 $23.62 $-0.82
Cash & equivalents $11.74B $10.35B $605.60M
Total debt $60.68B $30.76B –
Shares (diluted) 1.29B 217.60M 233.82M
Enterprise value $58.51B -$48.62B $1.25B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVSELVHIMS
P/E 10.4x 18.1x -24.2x
P/FCF 7.3x 14.3x 145.7x
P/Operating cash flow 6.1x 12.2x 25.6x
P/S 0.3x 0.5x 1.6x
P/B 1.4x 2.1x 13.0x
P/Tangible book 2.0x 2.7x -110.0x
EV/EBITDA 8.2x 9.6x -33.4x
EV/EBIT 10.6x 11.4x -16.8x
EV/Revenue 0.4x 0.4x 1.4x
EV/FCF 10.3x 13.5x 123.2x
EV/Operating cash flow 8.6x 11.6x 21.7x
PEG (3Y EPS CAGR) 1.22 -7.75 0.35

Growth

14 metrics
MetricCVSELVHIMS
Revenue growth (1Y) 6.7% 3.6% 29.8%
Revenue CAGR (3Y) 6.5% 6.2% 53.6%
Gross profit growth (1Y) 5.3% 4.3% 10.4%
Gross profit CAGR (3Y) 10.9% 5.5% 41.7%
Operating income growth (1Y) 206.4% -9.2% -302.1%
Operating income CAGR (3Y) 2.4% -4.2% -78.8%
Net income growth (1Y) 2,369% -7.4% -242.6%
Net income CAGR (3Y) 8.6% -5.2% -74.8%
EPS growth (1Y) 2,213% -4.5% -251.7%
EPS CAGR (3Y) 8.5% -2.3% -68.7%
Operating cash flow growth (1Y) 105.4% 54.6% -44.6%
Operating cash flow CAGR (3Y) 9.9% -7.2% 59.0%
Free cash flow growth (1Y) 147.4% 72.9% -76.3%
Free cash flow CAGR (3Y) 11.3% -7.6% -3.1%

Profitability

14 metrics
MetricCVSELVHIMS
Gross margin 44.2% 26.4% 63.8%
EBITDA margin 4.7% 4.6% -4.1%
Operating margin 3.6% 3.8% -8.1%
Pretax margin 2.9% 3.1% -7.7%
Net margin 2.6% 2.5% -6.6%
FCF margin 3.7% 3.2% 1.1%
Operating cash flow margin 4.4% 3.8% 6.3%
Return on equity 13.8% 11.4% -65.9%
Return on assets 4.3% 4.0% -6.2%
Return on invested capital 9.7% 8.3% –
Return on capital employed 9.2% 9.6% -10.8%
Asset turnover 1.6x 1.6x 0.8x
Cash conversion (OCF / net income) 1.7x 1.5x -0.9x
Stock comp / revenue 0.2% 0.1% 6.2%

Financial Health

11 metrics
MetricCVSELVHIMS
Debt / assets 23.5% 24.1% –
Debt / equity 0.8x 0.7x –
Net debt / EBITDA 2.3x -0.5x –
Debt / FCF 3.9x 4.7x –
Liabilities / assets 68.7% 65.0% 90.0%
Equity / assets 31.3% 35.0% 10.0%
Interest coverage 4.9x 5.3x –
Current ratio 0.9x 1.5x 0.9x
Quick ratio 0.8x 1.2x 0.8x
Cash ratio 0.2x 0.8x 0.5x
Altman Z-score 2.51 3.06 1.29

Shareholder Returns

7 metrics
MetricCVSELVHIMS
Dividend yield 3.0% 1.6% –
Net buyback yield -0.4% 2.2% 1.3%
Shareholder yield 2.6% 3.8% 1.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVSELVHIMS
Forward P/E 10.2xFY2026 14.3xFY2026 –
EPS, next fiscal year $8.80FY2026 $30.12FY2026 $-0.93FY2026
EPS growth, next FY +30.4%FY2026 -0.6%FY2026 -282.4%FY2026
EPS growth, the year after +1.1% +4.2% –
Revenue, next fiscal year $431.16BFY2026 $211.92BFY2026 $3.28BFY2026
Revenue growth, next FY +7.2%FY2026 +7.3%FY2026 +39.8%FY2026
Revenue growth, the year after -5.3% +0.0% +25.4%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVSELVHIMS
Held by institutions 89.1% 91.8% 69.3%
Institutions holding 2,074 1,615 510
Change in shares held, QoQ +3.5% +1.7% +4.4%
Institutions buying 1,103 862 325
Institutions selling 733 542 130
Buyers to sellers 1.50 1.59 2.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVSELVHIMS
CVS 1.00 0.42 -0.05
ELV 0.42 1.00 0.01
HIMS -0.05 0.01 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CVS, ELV and HIMS?

Cvs Health (CVS) is the largest by market capitalisation: Cvs Health (CVS) $109.76B, Elevance Health (ELV) $93.96B, Hims & Hers Health (HIMS) $4.13B.

Which stock is cheaper, CVS, ELV and HIMS?

Cvs Health (CVS) trades on the lowest price-to-earnings ratio (Cvs Health (CVS) 9.9x, Elevance Health (ELV) 18.3x, Hims & Hers Health (HIMS) -21.7x). On next year's consensus earnings, Cvs Health (CVS) is cheapest (Cvs Health (CVS) 10.2x, Elevance Health (ELV) 14.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Hims & Hers Health (HIMS) grew revenue fastest over the trailing twelve months: Cvs Health (CVS) +6.7%, Elevance Health (ELV) +3.6%, Hims & Hers Health (HIMS) +29.8%.

Which company is more profitable?

Cvs Health (CVS) has the highest net margin (Cvs Health (CVS) 2.6%, Elevance Health (ELV) 2.5%, Hims & Hers Health (HIMS) -6.6%). On return on invested capital, Cvs Health (CVS) leads (Cvs Health (CVS) 9.7%, Elevance Health (ELV) 8.3%).

Which stock has performed better?

Over the past year Elevance Health (ELV) returned the most: Cvs Health (CVS) +13.9%, Elevance Health (ELV) +37.0%, Hims & Hers Health (HIMS) -49.8%. Over five years, Hims & Hers Health (HIMS) compounded fastest (Cvs Health (CVS) -0.9%/yr, Elevance Health (ELV) +0.8%/yr, Hims & Hers Health (HIMS) +18.0%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Cvs Health (CVS) has been the steadiest (Cvs Health (CVS) 35.2%, Elevance Health (ELV) 35.8%, Hims & Hers Health (HIMS) 91.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CVS, ELV and HIMS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Cvs Health (CVS) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.